| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-07-15 | Rigontec (Germany) | chairman of the board of directors | nomination | Cancer - Oncology - Infectious diseases | Nomination | |
| 2015-07-14 | Fate Therapeutics (USA - CA) Regents of the University of Minnesota (MN) | natural killer (NK) cell-based cancer immunotherapeutics | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-07-14 | MDxHealth (Belgium) | nomination |
Cancer - Oncology - Diagnostic | Nomination | ||
| 2015-07-14 | Noxxon Pharma (Germany) | nomination |
Nomination | |||
| 2015-07-13 | Alcobra (Israel) | nomination |
Nomination | |||
| 2015-07-13 | Atyr Pharma (USA - CA) | resignation |
Rare diseases | Resignation | ||
| 2015-07-10 | apceth (Germany) the Center for Molecular Medicine Cologne (CMMC)University of Cologne (Germany) |
|
solid tumors, hematological malignancies | research - development - R&D | Cancer - Oncology | Research agreement |
| 2015-07-09 | Epizyme (USA - MA) Celgene (USA - NJ) | histone methyltransferase (HMT) inhibitors | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2015-07-09 | AstraZeneca (UK) Tillotts Pharma (Switzerland) Zeria Pharmaceutical (Japan) | Entocort® (budesonide) | mild to moderate Crohn’s disease, ulcerative colitis | product acquisition |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Product acquisition |
| 2015-07-08 | Sanofi-Aventis (France) Medicine for Malaria Venture | malaria treatments | malaria | R&D |
Infectious diseases - Parasitic diseases | R&D agreement |
| 2015-07-08 | Integragen (France) AP - HP (Assistance Publique - Hôpitaux de Paris) (France) Georges Pompidou European Hospital (HEGP) (France) | high-throughput sequencing techniques | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2015-07-08 | Galmed Pharmaceuticals (Israel) One Way Liver Genomics (Spain) | blood-based companion diagnostic tool for Aramchol™ | NASH (non-alcoholic steatohepatitis) | development - licensing | Hepatic diseases - Liver diseases | Licensing agreement |
| 2015-07-07 | Molecular Partners (Switzerland) Allergan (Ireland) | MP0112 | retinal diseases | milestone |
Ophtalmological diseases | Milestone |
| 2015-07-07 | Allergan (Ireland) Merck&Co (USA - NJ) | MK-1602, MK-8031 | treatment and prevention of migraine | licensing |
CNS diseases | Licensing agreement |
| 2015-07-07 | Paion (Germany) | resignation |
Resignation | |||
| 2015-07-07 | Incyte (USA - DE) Vanderbilt University Medical Center (USA - TN) | collaboration R&D |
Cancer - Oncology | Collaboration agreement | ||
| 2015-07-07 | Oramed Pharmaceuticals (Israel) Sinopharm Capital Management (China) | licensing investment |
Metabolic diseases | Licensing agreement | ||
| 2015-07-07 | Oasmia Pharmaceutical (Sweden) | new subsidiary in the US | establishment of a new subsidiary in the US |
Veterinary medicine | Establishment of a new subsidiary in the US | |
| 2015-07-07 | Autolus (UK) | head of manufacturing, head of intellectual property | nomination | Cancer - Oncology | Nomination | |
| 2015-07-06 | Retrophin (USA - CA) Sanofi (France) | Rare Pediatric Disease Priority Review Voucher (PPRV) | commercialisation | Rare diseases | Commercialisation agreement |
